Skip to main content
OpenTrials
Completed

NCT Number: NCT01067105

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic Rhinitis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Perennial Allergic Rhinitis Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Nose Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Respiratory Tract Diseases Rhinitis Rhinitis, Allergic Rhinitis, Allergic, Perennial

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Allergy and Asthma Specialists Group, Huntington Beach, California, United States

Loading trial locations.

About this study

This is a 6-month multi-center, open-label, long-term safety extension study in subjects who have completed Study 060-633 (NCT00953147). This study is designed to evaluate the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily to male and female subjects 12 years or older diagnosed with perennial allergic rhinitis (PAR). This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has successfully completed all visits of Study 060-633.
  • Subject has given written informed consent and assent, including privacy authorization as well as adherence to concomitant medication withholding periods, prior to participation.
  • Subject is male or female 12 years and older.
  • Subject must be in general good health (defined as the absence of any clinically relevant abnormalities as determined by the Investigator) based on screening physical examination, clinical laboratory tests, and medical history.
  • Subject, if female 65 years of age or younger, must have a negative urine pregnancy test (performed at Visit 1). Females of childbearing potential must be instructed to and agree to avoid pregnancy during the study and must use an acceptable method of birth control:
  • An oral contraceptive, an intrauterine device (IUD), implantable contraceptive, transdermal or injectable contraceptive for at least 1 month prior to entering the study with continued use throughout the study and for thirty days following study participation.
  • Barrier method of contraception, eg, condom and/or diaphragm with spermicide while participating in the study.
  • Abstinence.

Exclusion criteria

  • Female subject who is pregnant or lactating.
  • History of physical findings of nasal pathology, including nasal polyps.
  • Subject has any condition that, in the judgment of the investigator, would preclude the subject from completing the study.

Treatment and study plan

ciclesonide HFA 160 μg

Drug

ciclesonide HFA 160 μg once daily

Primary outcomes

  1. Percentage of Subjects Experiencing Adverse Events (AEs)

    Time frame: Weeks 1-26

  2. Percentage of Subjects Experiencing Serious Adverse Events (SAEs)

    Time frame: Weeks 1-26

  3. Percentage of Subjects Who Discontinue Due to AEs.

    Time frame: Weeks 1-26

Secondary outcomes

  1. Percentage of Subjects Experiencing Local Nasal AEs

    Time frame: Weeks 1-26

    Local Nasal adverse events are defined as adverse events occurring in the middle ear, nose, throat, and upper respiratory tract down to the larynx, anatomic regions.

  2. Change From Baseline in Daily Subject-reported AM Reflective TNSS Averaged Over the 6-month Treatment Period.

    Time frame: Baseline and Weeks 1-26

    TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

    0 = absent

    • = mild
    • = moderate
    • = severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the 6-month treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

  3. Change From Baseline in Daily Subject-reported AM Instantaneous TNSS Averaged Over the 6-month Treatment Period.

    Time frame: Baseline and Weeks 1-26

    TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

    0 = absent

    • = mild
    • = moderate
    • = severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six month treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

  4. Change From Baseline in Daily Subject-reported AM Reflective TNSS at Each Month Over the 6-month Treatment Period.

    Time frame: Baseline and Months 1, 2, 3, 4, 5, and 6

    TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

    0 = absent

    • = mild
    • = moderate
    • = severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the month treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

  5. Change From Baseline in Daily Subject-reported AM Instantaneous TNSS at Each Month Over the 6-month Treatment Period.

    Time frame: Baseline and Months 1, 2, 3, 4, 5, 6

    TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

    0 = absent

    • = mild
    • = moderate
    • = severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the month treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

  6. Ratio (Reported as Percentage) of Correct Advances of the Dose Indicator Out of Expected Advances

    Time frame: Weeks 0-12

    Ratio of correct advance is defined as the (number of doses actuated/number of doses reported) * 100% and therefore reported as a percentage.

  7. Number of Devices With Actuation Consistency

    Time frame: Weeks 0-6 and 6-12

    Actuation consistency is defined as a dose indicator count within ±20% of the subject self report of study medication administration

  8. Percentage of Devices With Actuation Consistency

    Time frame: Weeks 0-6 and 6-12

    Actuation consistency is defined as a dose indicator count within ±20% of the subject self report of study medication administration

  9. Number of Devices With Major Discrepancies

    Time frame: Weeks 0-6 and 6-12

    A major discrepancy is defined as a discrepancy of >20 actuations between the dose indicator and subject self report of study medication administration

  10. Percentage of Devices With Major Discrepancies

    Time frame: Weeks 0-6 and 6-12

    A major discrepancy is defined as a discrepancy of >20 actuations between the dose indicator and subject self report of study medication administration

  11. Number of Subjects Responding to the Subject Satisfaction Dose Indicator Survey

    Time frame: Weeks 6 and 12

    Participants responding to a survey that consisted of 7 questions assessing subject satisfaction with the dose indicator.

Sponsors and collaborators

Lead sponsor

Sumitomo Pharma America, Inc.

Industry

Registry information

Official study title

A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Feb 11, 2010
Registry last updated
Jun 13, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.